Analysis
BlossomHill Therapeutics filed to go public on the Nasdaq Global Select Market under the proposed ticker BLSM, targeting a $100 million raise with J.P. Morgan, Leerink Partners and Guggenheim Securities leading the offering, according to [TradingView News](https://www.tradingview.com/news/tradingview:d634ba32b6bba:0-blossomhill-therapeutics-clinical-stage-oncology-biotech-files-for-nasdaq-global-select-market-ipo/).
A Multi-Program Oncology Pipeline
The clinical-stage company, founded in 2020, has raised more than $257 million privately and reported a $60.6 million net loss in 2025. Its most advanced program, EGFR inhibitor BH-30643, is in a global Phase 1/2 trial targeting EGFR-mutant non-small cell lung cancer, with proceeds earmarked to push that program forward alongside BH-30236, a CLK blocker being evaluated for relapsed or refractory acute myeloid leukemia, and IND-enabling work on a third, pan-KRAS candidate.
Part of a Broader Summer Pipeline
BlossomHill's filing lands the same week Latigo Biotherapeutics priced its own $272 million IPO, reinforcing that the current biotech listing window is filling with genuine clinical-stage companies across multiple disease categories -- oncology and non-opioid pain, in these two cases -- rather than concentrating in a single hot therapeutic area the way earlier IPO cycles sometimes did.
What to watch: whether BlossomHill's roadshow produces pricing at, above, or below its initial $100 million target once it sets terms, and whether its multi-program pipeline structure -- spreading risk across three separate cancer indications -- proves more or less attractive to public investors than Latigo's more concentrated, single-mechanism bet.
